Risk of COVID-19 after natural infection or vaccination

BACKGROUND: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmoni...

Descripción completa

Detalles Bibliográficos
Autores principales: Rick, Anne-Marie, Laurens, Matthew B., Huang, Ying, Yu, Chenchen, Martin, Thomas C.S., Rodriguez, Carina A., Rostad, Christina A., Maboa, Rebone M., Baden, Lindsey R., El Sahly, Hana M., Grinsztejn, Beatriz, Gray, Glenda E., Gay, Cynthia L., Gilbert, Peter B., Janes, Holly E., Kublin, James G., Huang, Yunda, Leav, Brett, Hirsch, Ian, Struyf, Frank, Dunkle, Lisa M., Neuzil, Kathleen M., Corey, Lawrence, Goepfert, Paul A., Walsh, Stephen R., Follmann, Dean, Kotloff, Karen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518569/
https://www.ncbi.nlm.nih.gov/pubmed/37738833
http://dx.doi.org/10.1016/j.ebiom.2023.104799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518569/
https://www.ncbi.nlm.nih.gov/pubmed/37738833
http://dx.doi.org/10.1016/j.ebiom.2023.104799

Ejemplares similares